SOS1 Inhibitor Combination Therapy for Indirect RAS Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for directly or indirectly inhibiting RAS proteins in cancer treatment are challenging due to their picomolar affinity and wide protein-protein interaction surfaces, making it difficult to develop effective small molecule drugs, and existing SOS1 inhibitors are still in early stages of development.
Innovation Solution
A pharmaceutical composition comprising a novel compound of Formula I or its solvate, stereoisomer, or pharmaceutically acceptable salt, combined with an anticancer agent, targets the SOS1 catalytic site to inhibit SOS1-mediated activation of RAS-family proteins, thereby preventing oncogenic signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If direct inhibition of RAS is attempted, then RAS activity can be blocked, but the picomolar affinity of GTP for the binding site and wide protein-protein interaction surface make it extremely difficult to develop effective small molecule drugs
Solution Approach 1:
The patent extracts and targets the GEF (SOS1) component that facilitates RAS activation, rather than attempting to directly inhibit RAS. By inhibiting SOS1, the patent prevents GTP reloading onto RAS, achieving indirect RAS inhibition while avoiding the structural challenges of direct RAS targeting.
Solution Approach 2:
The patent introduces SOS1 as an intermediary target in the RAS activation pathway. Instead of directly blocking RAS-GTP interaction, the invention uses SOS1 inhibitors to prevent the formation of active RAS-GTP complexes by blocking GDP release and GTP binding, thus mediating RAS inhibition through an accessible intermediate target.
2Reliability
If farnesyl transferase is targeted to indirectly inhibit RAS, then RAS activation can be reduced, but no approved drug has been prepared despite various studies
Solution Approach 1:
The patent shifts the target parameter from farnesyl transferase to SOS1, a different enzyme in the RAS activation pathway. This parameter change enables drug development with better pharmacological properties and clinical potential, as SOS1 inhibitors can be designed to specifically block the nucleotide exchange function without affecting other aspects of RAS biology.
3Reliability
If SOS1 inhibitors are developed to inhibit RAS activation, then oncogenic signaling can be prevented, but existing SOS1 inhibitors are still in early stages of development
Solution Approach 1:
The patent performs preliminary identification and characterization of SOS1 as a viable drug target with specific binding sites and mechanisms of action. By establishing the catalytic site and allosteric site of SOS1 and demonstrating their druggability, the invention prepares the groundwork for future drug development, enabling more rapid progression from target identification to clinical trials.
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
There is provided a pharmaceutical composition for preventing or treating cancer, comprising a novel compound having SOS1 inhibitory activity and an anticancer agent as active ingredients. The novel compound according to the present invention inhibits the interaction between SOS1 and RAS family proteins, or between SOS1 and RAC1, thereby exhibiting synergistic effects in the anticancer activity when combined with other anticancer agents. Accordingly, a pharmaceutical composition for treating cancer comprising the novel compound and an anticancer agent as active ingredients may be usefully used for preventing or treating cancer.